EyePoint Q1 YUTIQ revenue up 60% to $7.4M; DAVIO 2 top-line data on track for Q4 2023

EyePoint, Inc.

2023-Q1 EPS reported -$0.56 revenue$7,683,000

YUTIQ net product revenue $7.4M, up 60% YoY; customer demand 930 units (+43% YoY).
Net loss $21.2M ($0.56/share); cash and investments $122.5M, down from $144.6M at Dec 31, 2022.
Phase 2 DAVIO 2 trial for wet AMD fully enrolled (160 patients, oversubscribed); topline data expected Q4 2023.
Phase 2 PAVIA trial for NPDR enrollment accelerated to 60 patients; data expected H1 2024; Phase 3 initiation advanced.
Leased 40,000 sq ft manufacturing facility in Northbridge, MA; awarded $1.9M state/local grants; cash runway into H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

EyePoint, Inc. reported financial results for first quarter ended March 31, 2023.

Period: first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced financial results for the first quarter ended March 31, 2023 and highlighted recent corporate developments.

View on SEC.gov

Browse all earnings releases →

EyePoint, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-016879

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.